Regulating microglial miR-155 transcriptional phenotype alleviates Alzheimer's-induced retinal vasculopathy by limiting Clec7a/Galectin-3+ neurodegenerative microglia
- PMID: 36076283
- PMCID: PMC9461176
- DOI: 10.1186/s40478-022-01439-z
Regulating microglial miR-155 transcriptional phenotype alleviates Alzheimer's-induced retinal vasculopathy by limiting Clec7a/Galectin-3+ neurodegenerative microglia
Abstract
Single cell RNA sequencing studies identified novel neurodegeneration-associated microglial (MGnD/DAM) subtypes activated around cerebral amyloid plaques. Micro-RNA (miR)-155 of the TREM2-APOE pathway was shown to be a key transcriptional regulator of MGnD microglial phenotype. Despite growing interest in studying manifestations of Alzheimer's disease (AD) in the retina, a CNS organ accessible to noninvasive high-resolution imaging, to date MGnD microglia have not been studied in the AD retina. Here, we discovered the presence and increased populations of Clec7a+ and Galectin-3+ MGnD microglia in retinas of transgenic APPSWE/PS1L166P AD-model mice. Conditionally targeting MGnD microglia by miR-155 ablation via the tamoxifen-inducible CreERT2 system in APPSWE/PS1L166P mice diminished retinal Clec7a+ and Galectin-3+ microglial populations while increasing homeostatic P2ry12+ microglia. Retinal MGnD microglia were often adhering to microvessels; their depletion protected the inner blood-retina barrier and reduced vascular amyloidosis. Microglial miR-155 depletion further limits retinal inflammation. Mass spectrometry analysis revealed enhanced retinal PI3K-Akt signaling and predicted IL-8 and Spp1 decreases in mice with microglia-specific miR-155 knockout. Overall, this study identified MGnD microglia in APPSWE/PS1L166P mouse retina. Transcriptional regulation of these dysfunctional microglia mitigated retinal inflammation and vasculopathy. The protective effects of microglial miR-155 ablation should shed light on potential treatments for retinal inflammation and vascular damage during AD and other ocular diseases.
Keywords: Alzheimer’s disease; Inflammation; Microglia; Retinopathy; Vascular damage; microRNA.
© 2022. The Author(s).
Conflict of interest statement
O.B. is an inventor of a patent for use miR-155 inhibitors in neurodegenerative diseases. O.B. and M.A.M. are co-inventors of a patent for use of Galectin-3 inhibitors for treatment of glaucoma. O.B.: collaboration with Sanofi, GSK, Regulus Therapeutics; research funding from Sanofi, GSK, miRagen Therapeutics, honoraria for lectures, consultancy: Camp4.
Figures
References
-
- Antes R, Salomon-Zimri S, Beck SC, Garcia Garrido M, Livnat T, Maharshak I, Kadar T, Seeliger M, Weinberger D, Michaelson DM. VEGF Mediates ApoE4-Induced neovascularization and synaptic pathology in the choroid and retina. Curr Alzheimer Res. 2015;12:323–334. doi: 10.2174/1567205012666150325182504. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 GM132668/GM/NIGMS NIH HHS/United States
- R21 NS104609/NS/NINDS NIH HHS/United States
- R01 AG075509/AG/NIA NIH HHS/United States
- R01 EY027921/EY/NEI NIH HHS/United States
- K12 EY016335/EY/NEI NIH HHS/United States
- R21 NS101673/NS/NINDS NIH HHS/United States
- R01 AG075998/AG/NIA NIH HHS/United States
- K08 EY030160/EY/NEI NIH HHS/United States
- R01 AG056478/AG/NIA NIH HHS/United States
- R01 AG051812/AG/NIA NIH HHS/United States
- R01 NS088137/NS/NINDS NIH HHS/United States
- R21 AG076982/AG/NIA NIH HHS/United States
- R01 AG055865/AG/NIA NIH HHS/United States
- R01 AG054672/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
